EUVIMEDEUVIMED entdecken
Crossref

Molecular Characterization of Resistance to Second-Line Anti-Mycobacterial Drugs among Clinical Isolates of Multidrug-Resistant Mycobacterium tuberculosis

Shadi Habibnia, Morteza Karami-Zarandi, Saeed Zaker, Zohreh Ghalavand, Farahnoosh Doustdar, Gita Eslami, Hossein Kazemian

Clinical Laboratory · 2023

DOI: 10.7754/clin.lab.2022.220211 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Laboratory, 2023. Verfasst von Shadi Habibnia und 6 weiteren Autor:innen. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Extensively Drug-Resistant Tuberculosis, Tuberculosis, Multidrug-Resistant. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The emergence of multidrug resistance and extensively drug-resistant tuberculosis is a serious public health crisis. Using rapid and inexpensive molecular methods such as HRM assay in the detection of second-line drugs resistance in M. tuberculosis would be helpful in the treatment and control of XDR tuberculosis cases. METHODS: MDR-TB isolates were collected from Iranian tuberculosis laboratories. Drug susceptibility test performed via the indirect proportion method utilizing LJ Medium. Susceptibility to ciprofloxacin, ofloxacin, amikacin, kanamycin, and capreomycin, as second-line anti-tuberculosis agents were assessed. Single point mutations in gyrA, rrs and eis genes were detected via HRM assay and DNA sequencing. RESULTS: A DST test was performed for 56 MDR isolates and at least 27 (48.2%) isolates were resistant to CIP or OFL. Also, 14 (25%), 12 (21.4%), and 15 (26.7%) isolates were resistant to capreomycin, amikacin, and kanamycin, respectively. D94G, A90V, and G88C mutations were the most frequent mutations in gyrA gene. Also, A1401G mutation was detected more than the other mutations in rrs gene. CONCLUSIONS: The frequency of CIP/OFL and AMK/CAP/KAN-resistant TB is considerable among Iranian tuberculosis cases. HRM assay is a rapid and inexpensive test and can detect important mutation-based drug resistance in MDR-TB and XDR-TB isolates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisExtensively Drug-Resistant TuberculosisTuberculosis, Multidrug-ResistantHumansAmikacinCapreomycinIranDrug Resistance, Multiple, BacterialAntitubercular AgentsKanamycinMutationMicrobial Sensitivity Tests

Substanzen

AmikacinCapreomycinAntitubercular AgentsKanamycin

Zitieren

APA

Habibnia, S., Karami-Zarandi, M., Zaker, S., Ghalavand, Z., Doustdar, F., Eslami, G., & Kazemian, H. (2023). Molecular Characterization of Resistance to Second-Line Anti-Mycobacterial Drugs among Clinical Isolates of Multidrug-Resistant Mycobacterium tuberculosis. Clinical Laboratory. https://doi.org/10.7754/clin.lab.2022.220211

Vancouver

Habibnia S, Karami-Zarandi M, Zaker S, Ghalavand Z, Doustdar F, Eslami G, et al. Molecular Characterization of Resistance to Second-Line Anti-Mycobacterial Drugs among Clinical Isolates of Multidrug-Resistant Mycobacterium tuberculosis. Clinical Laboratory. 2023. doi:10.7754/clin.lab.2022.220211

BibTeX
@article{Habibnia2023,
  author = {Habibnia, Shadi and Karami-Zarandi, Morteza and Zaker, Saeed and Ghalavand, Zohreh and Doustdar, Farahnoosh and Eslami, Gita and Kazemian, Hossein},
  title = {Molecular Characterization of Resistance to Second-Line Anti-Mycobacterial Drugs among Clinical Isolates of Multidrug-Resistant Mycobacterium tuberculosis},
  journal = {Clinical Laboratory},
  year = {2023},
  doi = {10.7754/clin.lab.2022.220211}
}
Kostenlos starten →